Learning from the EMA experience: common CMC deficiencies in marketing authorisation applications over the past
Dolores Hernán Pérez de la Ossa1, Friederike Haas1, Robert N Bream1
1European Medicines Agency, Pharmaceutical Quality Office, Human Division, Amsterdam, the Netherlands.
None:
Here, we present an analysis of major objections (MOs) raised on quality aspects during review of marketing authorisation applications (MAAs) for new medicines via the centralised procedure in the European Union (EU). The review covers a 10-year period by analysing data from 2013, 2018, and 2023. We identify common deficiencies, which should help developers prepare dossiers aligned with EU and global standards and avoid delays to approval of medicines, thereby improving patient access to medicines. The most common deficiencies are correlated with specific product types, recent public health crises, new legal frameworks, and the publication or revision of guidance.
More Related Videos
14:14Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
Published on: February 28, 2014
06:37Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
Published on: September 15, 2023
Related Concept Videos
Drug Regulation
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
Clinical Trials: Overview
Preclinical Development: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
